HeartBeam Inc. (NASDAQ: BEAT) FAQ: Revolutionizing Cardiac Care with Cable-Free ECG Technology

What is HeartBeam Inc. developing?

HeartBeam Inc. is developing the first cable-free system capable of synthesizing a 12-lead ECG from 3D, non-coplanar electrical signals captured in real time, enabling patients to record their symptoms anywhere, anytime.

How does the HeartBeam System benefit patients?

The HeartBeam System allows patients to record an ECG in 30 seconds at home or anywhere when symptoms occur, reducing delays in care and eliminating the need for wires, complex setup, or clinical staff.

What is the current FDA status of the HeartBeam System?

The HeartBeam System is FDA cleared for arrhythmia assessment, with additional FDA review underway for its 12-lead ECG synthesis software for the same indication.

How does HeartBeam’s partnership with AccurKardia enhance its solution?

The partnership with AccurKardia enhances HeartBeam’s arrhythmia solution by integrating an FDA-cleared automated rhythm interpretation software, improving the system’s diagnostic capabilities.

What intellectual property does HeartBeam hold?

HeartBeam holds 20 issued patents, with additional allowed and pending applications, protecting its proprietary hardware, software, and algorithmic capabilities.

When is the commercial launch of the HeartBeam System expected?

The commercial launch is expected to be imminent, targeting a $500 million concierge SAM and broader multibillion-dollar patient pay market.

What makes HeartBeam’s approach unique compared to traditional ECGs?

HeartBeam’s patented approach delivers similar accuracy to conventional 12-lead ECGs for arrhythmia detection but in a cable-free format, making it accessible outside traditional medical settings.

Where can I find more information about HeartBeam Inc.?

More information about HeartBeam Inc. is available in the company’s newsroom at https://ibn.fm/BEAT and on their website HeartBeam (NASDAQ: BEAT).